Whales with a great deal of cash to invest have actually taken a visibly bearish position on Praxis Accuracy Medication
Taking a look at alternatives history for Praxis Accuracy Medication (NASDAQ: PRAX) we found 8 trades.
If we think about the specifics of each trade, it is precise to state that 12% of the financiers opened trades with bullish expectations and 50% with bearish.
From the total spotted trades, 2 are puts, for an overall quantity of $105,000 and 6, calls, for an overall quantity of $297,017.
What’s The Cost Target?
Considering the Volume and Open Interest on these agreements, it appears that whales have actually been targeting a rate variety from $65.0 to $300.0 for Praxis Accuracy Medication over the last 3 months.
Evaluating Volume & & Open Interest
In today’s trading context, the typical open interest for alternatives of Praxis Accuracy Medication stands at 74.17, with an overall volume reaching 97.00. The accompanying chart marks the development of both call and put alternative volume and open interest for high-value sell Praxis Accuracy Medication, positioned within the strike rate passage from $65.0 to $300.0, throughout the last thirty days.
Praxis Accuracy Medication Choice Volume And Open Interest Over Last one month
Considerable Choices Trades Found:
| Sign | PUT/CALL | Trade Type | Belief | Exp. Date | Ask | Quote | Cost | Strike Cost | Overall Trade Cost | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PRAX | CALL | TRADE | BEARISH | 01/16/26 | $ 103.4 | $ 101.0 | $ 101.0 | $ 65.00 | $ 101.0 K | 82 | 10 |
| PRAX | PUT | TRADE | NEUTRAL | 12/18/26 | $ 68.5 | $ 63.5 | $ 66.0 | $ 185.00 | $ 66.0 K | 10 | 10 |
| PRAX | CALL | SWEEP | BEARISH | 12/19/25 | $ 7.9 | $ 7.9 | $ 7.9 | $ 200.00 | $ 53.7 K | 136 | 69 |
| PRAX | PUT | SWEEP | BEARISH | 11/21/25 | $ 130.0 | $ 125.0 | $ 130.0 | $ 300.00 | $ 39.0 K | 0 | 0 |
| PRAX | CALL | SWEEP | NEUTRAL | 12/18/26 | $ 77.0 | $ 72.5 | $ 74.56 | $ 120.00 | $ 37.3 K | 100 | 5 |
About Praxis Accuracy Medication
Praxis Accuracy Medicines Inc is a clinical-stage biopharmaceutical business. The company is taken part in equating hereditary insights into the advancement of treatments for clients impacted by main nerve system conditions defined by a neuronal excitation-inhibition imbalance. The business has actually produced 3 clinical-stage item prospects, ulixacaltamide (previously referred to as PRAX-944), vormatrigine (previously referred to as PRAX-628), and relutrigine (previously referred to as PRAX-562), in addition to PRAX-020 which has actually been in-licensed by UCB Biopharma SRL, or UCB.
Having actually analyzed the alternatives trading patterns of Praxis Accuracy Medication, our attention now turns straight to the business. This shift enables us to look into its present market position and efficiency
Existing Position of Praxis Accuracy Medication
- Presently trading with a volume of 880,309, the PRAX’s rate is up by 1.31%, now at $174.0.
- RSI readings recommend the stock is presently might be overbought.
- Prepared for revenues release remains in 0 days.
What Experts Are Stating About Praxis Accuracy Medication
5 market specialists have actually just recently provided rankings for this stock, with an agreement target rate of $233.0.
Turn $1000 into $1270 in simply 20 days?
20-year professional alternatives trader exposes his one-line chart strategy that reveals when to purchase and offer. Copy his trades, which have actually had balanced a 27% earnings every 20 days. Click on this link for gain access to
* An expert from Wedbush has actually chosen to preserve their Underperform ranking on Praxis Accuracy Medication, which presently sits at a rate target of $73.
* An expert from HC Wainwright & & Co. has actually chosen to preserve their Buy ranking on Praxis Accuracy Medication, which presently sits at a rate target of $232.
* An expert from Deutsche Bank has actually chosen to preserve their Buy ranking on Praxis Accuracy Medication, which presently sits at a rate target of $280.
* Keeping their position, an expert from Chardan Capital continues to hold a Buy ranking for Praxis Accuracy Medication, targeting a rate of $330.
* Constant in their examination, an expert from Needham keeps a Buy ranking on Praxis Accuracy Medication with a target rate of $250.
Options trading provides greater threats and possible benefits. Astute traders handle these threats by constantly informing themselves, adjusting their techniques, keeping an eye on several signs, and keeping a close eye on market motions. Stay notified about the current Praxis Accuracy Medication alternatives trades with real-time signals from Benzinga Pro.